Leadership
In an exclusive interview with Generics Bulletin, Aspargo Labs CEO Michael Demurjian discusses the importance of reformulated liquid oral suspension drugs, while outlining plans to launch a smart device that connects patients and doctors.
Rounding up another important year in the fight against HIV, the MPP’s executive director Charles Gore speaks to Generics Bulletin about the organization’s biggest milestones in the past 12 months.
Medicines for Europe names a new president, the IGBA reveals its latest chair, and Chanelle and Xbrane announce fresh faces in key roles, in our latest round-up of off-patent industry appointments.
Insud Pharma chief executive Lucas Sigman has moved up to lead the IGBA’s CEO Advisory Committee, replacing Lupin chief Vinita Gupta at the helm. Meanwhile, Apotex president and CEO Allan Oberman has become vice-chair.
In the final instalment of his three-part interview with Generics Bulletin, Sandoz CEO Richard Saynor talks about opportunities on the horizon, including GLP-1s, ADCs and oligonucleotides – and explains why he has no interest in pursuing value added medicines.
In the second part of our exclusive interview with Richard Saynor, the Sandoz CEO discusses the importance of both the small-molecule generics and biosimilars businesses for the company, talking about portfolio selection and specific product opportunities for biosimilars while also contrasting the firm’s European and US generics leadership aspirations and approaches to the business.
In the first instalment of a three-part interview with Richard Saynor, the Sandoz CEO talks about the aftermath of the company’s spinoff from former parent Novartis and the work still left to do; the increasing prominence of biosimilars for Sandoz; the firm’s investments in manufacturing; thoughts on the potential for significant M&A; and future opportunities for the industry leader.
EuroAPI says it is moving “into a new chapter” after appointing another new CEO, marking the latest change in leadership after what has been a turbulent year for the European active pharmaceutical ingredients specialist.
Following its recent presentation of results for the third quarter of the 2024 fiscal year, Organon’s US biosimilars lead Jon Martin spoke to Generics Bulletin about the company’s adalimumab plans and strategy with upcoming launches, as well as how these will benefit from the firm’s focus on women’s health.
Europe risks “missing out on a massive opportunity” if it does not improve its efforts to recognize and take advantage of the benefits of value added medicines, according to Medicines for Europe sector chair and Pharmanovia CEO James Burt.
Korean biosimilars giant Samsung Bioepis and leading French generics firm Biogaran have both announced new leaders, while Xbrane Biopharma is looking for a fresh finance chief.
Setting out plans to support career development and create learning and networking opportunities for women in the UK generics and biosimilars industry, local off-patent association the BGMA has named Accord’s Clara Carter as chair of a new women’s networking group.
In the wake of its recent acquisition of dermatology assets from Canute Pharma, UK-based Aspire Pharma is looking to new frontiers of expansion in Europe and beyond. Chief executive Richard Condon talks to Generics Bulletin about the next steps on the niche generics and value added medicines firm’s journey.
Our latest roundup of off-patent industry appointments sees Lupin appointing a new president of global specialty, at the same times as several other organizations welcome fresh leadership.
Biocon Biologics chief commercial officer for advanced markets Matt Erick says the firm is a “quiet giant” in the biosimilars space, but speaks up about the firm’s plans to grow its business in Europe, explore in-licensing as well as in-house development, and capitalize on the upcoming loss of exclusivity for Stelara in the US.
As Sandoz publishes a report on US drug shortages – dissecting their root causes, the current policy landscape and recommendations for future improvements – the firm’s North America head and AAM chair Keren Haruvi speaks to Generics Bulletin about what can be done to alleviate continuing supply-chain failures.
Teva’s CEO Richard Francis has spoken candidly about the steps he has taken in order for Teva to reclaim its credibility, underpinned by the company’s ‘Pivot to Growth’ strategy.
Fresh leadership has been announced for the US Association for Accessible Medicines, with new president and CEO John Murphy joining the generics and biosimilars organization after serving in key roles at brand industry associations PhRMA and BIO.
Kamil Hamied, son of Cipla’s outgoing vice-chair M K Hamied, is set to re-join the company as non-executive director, following his "entrepreneurial journey." Does it signal a shift in the promoter group’s immediate considerations amid past stake sale speculation or mark routine top-level executive changes?
Chanelle Pharma has named a new chief executive officer and set out ambitious plans to expand its workforce, while Enzene Biosciences has appointed a new facility head and Perrigo has created a brand and digital role on its top management team.